Literature DB >> 31125275

Activation of liver X receptor up-regulates the expression of the NKG2D ligands MICA and MICB in multiple myeloma through different molecular mechanisms.

Maria Teresa Bilotta1, Maria Pia Abruzzese1, Rosa Molfetta1, Gianluca Scarno1, Cinzia Fionda1, Alessandra Zingoni1, Alessandra Soriani1, Tina Garofalo2, Maria Teresa Petrucci3, Maria Rosaria Ricciardi4, Rossella Paolini1, Angela Santoni1,5,6, Marco Cippitelli1.   

Abstract

NK cells have an important role in immunosurveillance of multiple myeloma (MM) progression, and their activity is enhanced by combination therapies able to regulate the expression of specific activating ligands. Liver X receptors (LXRs) are nuclear receptors and important regulators of intracellular cholesterol and lipid homeostasis. Moreover, they have regulatory roles in both cancer and immune response. Indeed, they can regulate inflammation and innate and acquired immunity. Furthermore, LXR activation directly acts in cancer cells (e.g., prostate, breast, melanoma, colon cancer, hepatocarcinoma, glioblastoma, and MM) that show an accumulation of cholesterol and alteration of LXR-mediated metabolic pathways. Here, we investigated the role of LXR and cholesterol on the expression of the NK cell-activating ligands major histocompatibility complex class I chain-related molecule A and B (MICA and MICB) in MM cells. The results shown in this work indicate that MM cells are responsive to LXR activation, which induces changes in the intracellular cholesterol content. These changes correlate with an enhanced expression of MICA and MICB in human MM cell lines and in primary malignant plasma cells, 2 ligands of the NK group 2D receptor (NKG2D)/CD314 activating receptor expressed in cytotoxic lymphocytes, rendering MM cells more sensitive to recognition, degranulation, and killing by NK cells. Mechanistically, we observed that LXR activation regulates MICA and MICB expression at different levels: MICA at the transcriptional level, enhancing mica promoter activity, and MICB by inhibiting its degradation in lysosomes. The present study provides evidence that activation of LXR, by enhancing NKG2D ligand expression, can promote NK cell-mediated cytotoxicity and suggests a novel immune-mediated mechanism involving modulation of intracellular cholesterol levels in cancer cells.-Bilotta, M. T., Abruzzese, M. P., Molfetta, R., Scarno, G., Fionda, C., Zingoni, A., Soriani, A., Garofalo, T., Petrucci, M. T., Ricciardi, M. R., Paolini, R., Santoni, A., Cippitelli, M. Activation of liver X receptor up-regulates the expression of the NKG2D ligands MICA and MICB in multiple myeloma through different molecular mechanisms.

Entities:  

Keywords:  LXR; cholesterol; natural killer

Mesh:

Substances:

Year:  2019        PMID: 31125275     DOI: 10.1096/fj.201900319R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  10 in total

1.  The Liver X Receptor Is Selectively Modulated to Differentially Alter Female Mammary Metastasis-associated Myeloid Cells.

Authors:  Liqian Ma; Hashni Epa Vidana Gamage; Srishti Tiwari; Chaeyeon Han; Madeline A Henn; Natalia Krawczynska; Payam Dibaeinia; Graeme J Koelwyn; Anasuya Das Gupta; Rafael Ovidio Bautista Rivas; Chris L Wright; Fangxiu Xu; Kathryn J Moore; Saurabh Sinha; Erik R Nelson
Journal:  Endocrinology       Date:  2022-07-01       Impact factor: 5.051

Review 2.  Post-translational Mechanisms Regulating NK Cell Activating Receptors and Their Ligands in Cancer: Potential Targets for Therapeutic Intervention.

Authors:  Rosa Molfetta; Alessandra Zingoni; Angela Santoni; Rossella Paolini
Journal:  Front Immunol       Date:  2019-10-31       Impact factor: 7.561

Review 3.  DNT Cell-based Immunotherapy: Progress and Applications.

Authors:  Yingrui Li; Kang Dong; Xueke Fan; Jun Xie; Miao Wang; Songtao Fu; Qin Li
Journal:  J Cancer       Date:  2020-03-31       Impact factor: 4.207

Review 4.  Lipid metabolism alteration contributes to and maintains the properties of cancer stem cells.

Authors:  Huangcan Li; Zhuoying Feng; Ming-Liang He
Journal:  Theranostics       Date:  2020-05-30       Impact factor: 11.556

Review 5.  Liver X Receptors: Regulators of Cholesterol Metabolism, Inflammation, Autoimmunity, and Cancer.

Authors:  Maria Teresa Bilotta; Sara Petillo; Angela Santoni; Marco Cippitelli
Journal:  Front Immunol       Date:  2020-11-03       Impact factor: 7.561

6.  Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition.

Authors:  Sara Petillo; Cristina Capuano; Rosa Molfetta; Cinzia Fionda; Abdelilah Mekhloufi; Chiara Pighi; Fabrizio Antonangeli; Alessandra Zingoni; Alessandra Soriani; Maria Teresa Petrucci; Ricciarda Galandrini; Rossella Paolini; Angela Santoni; Marco Cippitelli
Journal:  Cell Death Dis       Date:  2021-09-04       Impact factor: 8.469

Review 7.  Targeting cholesterol homeostasis in hematopoietic malignancies.

Authors:  Andrea Brendolan; Vincenzo Russo
Journal:  Blood       Date:  2022-01-13       Impact factor: 22.113

Review 8.  Our evolving understanding of how 27-hydroxycholesterol influences cancer.

Authors:  Liqian Ma; Wonhwa Cho; Erik R Nelson
Journal:  Biochem Pharmacol       Date:  2021-05-24       Impact factor: 5.858

Review 9.  Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?

Authors:  Aviad Ben-Shmuel; Guy Biber; Mira Barda-Saad
Journal:  Front Immunol       Date:  2020-02-21       Impact factor: 7.561

10.  FABP5, a Novel Immune-Related mRNA Prognostic Marker and a Target of Immunotherapy for Multiple Myeloma.

Authors:  Haipeng Jia; Xiaofen Zhang; Xinxin Liu; Ruifang Qiao; Yan Liu; Sulong Lv; Hongbo Zhu; Jie Wang; Qiuhong Kong; Hong Zhang; Zhirong Zhang
Journal:  Front Med (Lausanne)       Date:  2021-06-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.